AIDS Therapies

HU Enhances ddI and PMEA - Even Against Resistant HIV

Published in AIDS Weekly, August 30th, 1999

Hydroxyurea (HU) increases the action of other anti-HIV drugs - even against viral strains resistant to those drugs, a new study suggests.

HU, an anticancer agent of long standing, inhibits the cellular enzyme ribonucleotide reductase and leads to reduced pools of deoxynucleotide triphosphates (dNTPs). Reduced pools of dNTPs favor HIV uptake of nucleoside analog inhibitors of HIV reverse transcriptase.

As the most pronounced reduction of dNTP is among deoxyadenosine triphosphates (dATPs), Stanford researchers Sarah Palmer and colleagues explored the synergy between HU and three adenosine-based nucleoside-analog reverse transcriptase inhibitors...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry